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Abstract
Background: Astrocytes are an integral component of the blood–brain barrier (BBB) which may be compromised
by ischemic or traumatic brain injury. In response to trauma, astrocytes increase expression of the endopeptidase
matrix metalloproteinase (MMP)-9. Compromise of the BBB leads to the infiltration of fluid and blood-derived
proteins including albumin into the brain parenchyma. Albumin has been previously shown to activate astrocytes
and induce the production of inflammatory mediators. The effect of albumin on MMP-9 activation in astrocytes is
not known. We investigated the molecular mechanisms underlying the production of MMP-9 by albumin in
astrocytes.
Methods: Primary enriched astrocyte cultures were used to investigate the effects of exposure to albumin on the
release of MMP-9. MMP-9 expression was analyzed by zymography. The involvement of mitogen-activated protein
kinase (MAPK), reactive oxygen species (ROS) and the TGF-β receptor-dependent pathways were investigated using
pharmacological inhibitors. The production of ROS was observed by dichlorodihydrofluorescein diacetate
fluorescence. The level of the MMP-9 inhibitor tissue inhibitor of metalloproteinase (TIMP)-1 produced by astrocytes
was measured by ELISA.
Results: We found that albumin induces a time-dependent release of MMP-9 via the activation of p38 MAPK and
extracellular signal regulated kinase, but not Jun kinase. Albumin-induced MMP-9 production also involves ROS
production upstream of the MAPK pathways. However, albumin-induced increase in MMP-9 is independent of the
TGF-β receptor, previously described as a receptor for albumin. Albumin also induces an increase in TIMP-1 via an
undetermined mechanism.
Conclusions: These results link albumin (acting through ROS and the p38 MAPK) to the activation of MMP-9 in
astrocytes. Numerous studies identify a role for MMP-9 in the mechanisms of compromise of the BBB,
epileptogenesis, or synaptic remodeling after ischemia or traumatic brain injury. The increase in MMP-9 produced
by albumin further implicates both astrocytes and albumin in the acute and long-term complications of acute CNS
insults, including cerebral edema and epilepsy.
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Background
The blood–brain barrier (BBB) is composed of vascular
endothelium, basal lamina, pericytes and astrocyte foot
processes anchored by tight junctions [1-3]. The BBB
prevents fluid, macromolecules, and small molecules
from exiting the microvasculature and entering the brain
parenchyma. Compromise of the BBB by ischemic or
traumatic brain injury results in cytotoxic and vasogenic
edema, and is a major determinant of outcome after
neurological trauma [4-7].
The endopeptidase matrix metalloproteinase (MMP)-9
plays a pivotal role in BBB proteolysis after injury [8-10],
and contributes to cell death after prolonged seizures
[11]. MMP-9 degrades tight-junction proteins [12], regu-
lates N-methyl-D-aspartate (NMDA) receptor signaling
[3,13] and synaptic remodeling [3], also implicating this
proteinase in the mechanisms of long-term potentiation
and epileptogenesis [14]. Under normal conditions, the
proteolytic activity of MMPs including MMP-9 is regu-
lated by tissue inhibitor of matrix metalloproteinase
(TIMP)-1. Gene transfer and knockout approaches indi-
cate a protective role for TIMP-1 after cerebral ischemic
insults [15,16].
Endothelial cells are known to be the principal struc-
tural component of the BBB, but relatively less is known
about the function of astrocytes in the mechanisms lead-
ing to compromise of the BBB after injury. Astrocytes
play a major role in maintaining water homeostasis and
integrity of BBB under physiological and pathophysio-
logical conditions [17]. MMP-9 activation in astrocytes
can by induced by oxidative stress [18], thrombin [19],
tumor necrosis factor-α [20], or tissue plasminogen acti-
vator [21], and involves activation of mitogen-activated
protein kinases (MAPKs) [19,20].
Following disruption of the BBB, blood-derived pro-
teins including thrombin and albumin, penetrate into
the brain parenchyma. Albumin is taken up by astro-
cytes [22,23] and can then initiate a cascade of events
implicated in the mechanisms of epileptogenesis via acti-
vation of the transforming growth factor (TGF-β) recep-
tor [22,24]. Albumin also activates intracellular calcium
signaling pathways in astrocytes [25], and causes the re-
lease of inflammatory factors including monocyte
chemotactic protein (MCP)-1 [26], interleukin (IL)-1β,
nitric oxide and chemokine (C-X3-C motif ) ligand
(CX3CL)1 [27,28]. We have previously shown that acti-
vation of astrocytes by albumin involves MAPK path-
ways [27-29]. The effects of albumin on astrocyte
expression of MMP-9, and thereby the potential role of
albumin in the mechanisms leading to brain edema, are
unknown.
Understanding the complex effects of albumin and
other serum proteins on glial responses to acute brain
injuries has important implications for clinical practice.
Animal models of traumatic brain injury [30], intracorti-
cal hematoma [31], and stroke [32] indicate a neuropro-
tective role for albumin. The increase in mortality
associated with albumin treatment after traumatic brain
injury (TBI) [33] contrasts with the improved functional
outcome seen 2 years after ischemic stroke [34].
In this study, we investigated whether albumin acti-
vates the production of MMP-9 by astrocytes. We exam-
ined the involvement of MAPK pathways including p38
MAPK, extracellular signal regulated protein kinase
(ERK) and c-Jun N-terminal kinase (JNK) in these
responses. We also determined the role of reactive oxy-
gen species (ROS) and the role of TGF-β receptor path-
way in the production of MMP-9 induced by albumin in
astrocytes. We found that albumin induces an increase
in the level of MMP-9 and that this increase in MMP-9
is dependent on the activation of MAPK pathways and
ROS. These findings implicate albumin in the mechan-
isms of cerebral edema and epileptogenesis after brain
injury.
Methods
All experiments followed protocols approved by the In-
stitutional Animal Care and Use Committee of Chil-
dren’s Memorial Research Center, Chicago, Illinois.
Isolation and culture of primary astrocytes
Primary cortical astrocyte cultures were prepared
from Sprague-Dawley rat pups 1–3 days old (Charles
River, Wilmington, MA, USA), as described previously
[29,35]. Briefly, cortices were isolated and cleaned of
meninges in Ca2+ and Mg2+-free Hank’s balanced buf-
fered salt solution (HBSS). After trypsin digestion, the
cell suspension was filtered through a 40 μm filter, sepa-
rated by centrifugation, and resuspended in DMEM sup-
plemented with 10% FBS and 1% penicillin and
streptomycin. Cells were then transferred to 75 cm2
flasks, and cultured in humidified incubator at 37°C in
5% CO2, with media changed every 2 to 3 days. After 9
to 10 days in culture, enriched astrocyte cultures were
prepared by shaking the flasks at 200 rpm for 24 hours,
and the media containing floating microglia cells and
oligodendrocytes then removed and replaced. When
confluent, cells were lifted from the flask with 0.05%
trypsin/0.2% EDTA and plated into 12-well plates. Cells
were cultured to confluency in humidified incubator at
37°C in 5% CO2 with the media changed every 3 to
4 days. The enriched astrocyte cultures were composed
of more than 95% of astrocytes, as determined by stain-
ing using an anti-glial fibrillary acidic protein as the pri-
mary antibody and the nuclear staining dye DAPI as
previously described [28] (results not shown).
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Astrocyte activation with albumin
Culture media was changed to serum-free, phenol red-
free DMEM supplemented with 1%N2 supplement
(Gibco/Invitrogen, Carlsbad, CA, USA) 24 hours before
treatment. Cells were treated with either PBS (control)
or 0.1 mmol/l globulin-free and fatty acid-free BSA
(Sigma Aldrich, St. Louis, MO, USA). The concentration
of BSA used in this study is similar to that used in other
studies of the effects of exogenous albumin on primary
astrocytes or brain slice preparations [22,24], and corre-
sponds to 25% of the serum concentration. We have pre-
viously reported that this concentration of BSA does not
induce any change in cell viability [28].
Pharmacologic inhibition of mitogen-activated protein
kinases, transforming growth factor-β receptor signaling,
and reactive oxygen species
Cells were treated with inhibitors of the MAPK path-
ways: the p38 MAPK inhibitor SB203580, the MAPK
kinase (MEK)/ERK pathway inhibitor PD98059, JNK in-
hibitor SP600125 (Calbiochem, Gibbstown, NJ, USA).
The role of the TGF-β receptor pathway was investi-
gated by treating the cells with the TGF-β receptor I in-
hibitor SB431542 (Tocris, Ellisville, MO, USA) or the
specific Smad3 inhibitor (SIS3, Calbiochem, San Diego,
CA, USA). The role of ROS was determined by treating
the cells with the NADPH oxidase inhibitor diphenyle-
neiodonium chloride (DPI), polyethylene glycol–super-
oxide dismutase (PEG-SOD, 200U), or polyethylene
glycol–catalase (PEG- CAT, 200U) (all Sigma Aldrich).
For all conditions, the inhibitor or diluent was added to
the cells 30 minutes before treatment with PBS or BSA.
Quantification of mitogen-activated protein kinase
activation by western blotting
Cells lysates were prepared as described previously
[27,28,35]. Equal amounts of protein were determined
by the bicinchoninic acid protein assay (Pierce, Rock-
ford, IL, USA). Samples were added to 5× Laemmli sam-
ple buffer, heated at 90°C for 5 minutes, then separated
in a 10% gel (Mini-Protean TGX) and transferred to a
polyvinylidene fluoride membrane (all Bio-Rad,
Hercules, CA, USA). Membranes were blocked with
Tris-buffered saline containing 0.1% Tween-20 and 5%
non-fat dry milk for 1 hour at room temperature. Mem-
branes were then incubated overnight at 4°C with either
anti-phospho-p38 MAPK, anti-phospho-ERK1/2 or anti-
phospho-JNK (all Cell Signaling Technology, Danvers,
MA, USA), followed by incubation with horseradish per-
odixase-conjugated secondary antibodies for 1 hour at
room temperature. A chemiluminescent substrate was
used to detect signals. To measure the expression of the
total MAPK proteins, membranes were incubated with
antibodies to total p38 MAPK, ERK1/2, and JNK
respectively (all Cell Signaling Technology). Autoradiog-
raphy films were scanned and analyzed for relative
densitometry with Molecular Imaging software (version
5.0.2.30; Carestream, Rochester NY). Ratios of phospho-
to total p38 MAPK, ERK1/2, or JNK were calculated,
and data were normalized using the control group or the
BSA-treated group as 100%.
Gelatin zymography
Conditioned media underwent a purification step before
being used in a zymography assay as described previ-
ously [35]. Samples were resolved by electrophoresis in a
10% polyacrylamide gel containing gelatin (Invitrogen).
Thereafter, gels were washed four times in renaturing
buffer (Invitrogen) for 15 min each before incubating for
16 hr at 37°C in development buffer (Invitrogen). After
staining the gel with 0.1% Coomassie Brilliant Blue R-
250 (Bio-Rad), the gelatinolytic activities were visualized
as a clear band in the uniformly stained background.
The molecular weight of the gelatinase was estimated by
comparing the migration distance of the clear bands
with the distance migrated by markers of known mo-
lecular weight. The gels were scanned using white light
transillumination in an imaging system (Gel Logic 212
PRO; Carestream). The bands were analyzed for relative
densitometry using the Molecular Imaging software
(Carestream).
Detection of intracellular reactive oxygen species
production
Cells were treated with PBS, BSA, or 100 μmol/l of the
positive control tert-butyl hydroperoxide (TBHP; Invi-
trogen) for 90 min. The fluorogenic marker 5-(and-6)-
carboxy-2′,7′-dichlorodihydrofluorescein diacetate (car-
boxy-H2DCF-DA, Invitrogen) was used to monitor the
intracellular production of ROS. Cells were washed with
HBSS and incubated for 30 minutes with HBSS contain-
ing 25 μmol/l carboxy-H2DCF-DA at 37°C. Cell nuclei
were stained using Hoescht 33342 (Invitrogen). Cells
were washed with HBSS and visualized using an inverted
microscope (DM-IRB; Leica, Heerbrugg, Switzerland)
coupled with a camera (Retiga 4000R; QImaging, Surrey,
BC, Canada), and fluorescence images were acquired
using a fluorescence camera (ORCA ER; Hamamatsu.
Bridgewater, NJ, USA) camera and pseudocolored using
OpenLab 5.5 (Improvision, Waltham, MA, USA). The
fluorescence signal was assessed qualitatively.
ELISA
Levels of TIMP-1 in the cell culture media were mea-
sured by ELISA (R & D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
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Statistical analysis
Data are expressed as mean ± SEM. Time-course analysis
was performed using two-way repeated analysis of vari-
ance (ANOVA). Comparisons between multiple groups
were performed with ANOVA followed by Dunnett’s
multiple comparison, comparing all the groups to the
BSA-treated group. The criterion for statistical signifi-
cance was P< 0.05. GraphPad Prism (version 5.0;
GraphPad Software, Inc., San Diego, CA, USA) was used
for statistical analyses.
Results
Bovine serum albumin produces a time-dependent
increase in levels of MMP-9
Using zymography, we determined the effect of albumin
on the MMP-9 levels released in the conditioned media
at different time points (Figure 1). The release of MMP-
9 from astrocytes treated with albumin was time-
dependent. The increase in MMP-9 was detected at 24
hours after exposure to albumin, and was significantly
increased compared with control cells (Figure 1a,b). No
MMP-9 was detected in control media at any of the time
points investigated. MMP-2-related gelatinase activity
was detected in control media at all the time points
studied. Treatment of astrocytes with albumin did not
affect the levels of MMP-2 in media compared with con-
trol values (Figure 1c).
We then investigated whether the increase in MMP-9
was specific to the type of albumin (globulin- and fatty
acid-free BSA) and the species used in these experi-
ments. We treated astrocytes with the same concentra-
tion of either the BSA used above, or the fraction V
(FrV) preparation, which still contains fatty acids. We
measured the release of MMP-9 after 24 hours by zymo-
gram. Treatment with FrV and BSA both produced an
increase in MMP-9 compared with control cells (Fig-
ure 1d). Both rat serum albumin and human serum al-
bumin induced an increase in MMP-9 that was similar
to that produced by BSA. Thus, the increase in MMP-9
seen in astrocytes was also not dependent on the species
of origin of the albumin. None of the albumin prepara-
tions tested above induced a change in the level of
MMP-2 produced by astrocytes (data not shown). Fi-
nally, we examined whether the response to BSA was
specific by comparing it with the response to another
high molecular weight molecule. Cells treated with
0.1 mmol/l dextran (70 kDa) did not show any increase
in the level of MMP-9 compared with control cells (Fig-
ure 1d), and dextran did not induce any change in the
level of MMP-2 produced by astrocytes (data not
shown).
Figure 1 Albumin stimulated an increase in the release of MMP-9 released in the conditioned media by astrocytes. Astrocytes were
exposed to control PBS (−) or BSA (+). The conditioned media were collected after 0.5, 1.5, 6 and 24 hours and analyzed by gelatin zymography.
(a) Representative zymogram showing a time-dependent increase in matrix metalloproteinase (MMP)-9; (b) there was a significant increase in the
level of MMP-9 released 24 hours after BSA treatment compared with the control group; (c) the level of MMP-2 measured after BSA treatment
was similar to that of the control group at all time points; (d) treatment with fraction V (FrV) BSA also induced an increase in the level of MMP-9
released from astrocytes. Human serum albumin (HSA) and rat serum albumin (RSA) induced a similar increase in MMP-9 level to that seen with
BSA. Treatment with dextran (0.1 mmol/L) did not induce any change in the level of MMP-9 in astrocytes. Data are representative of mean± SEM
of three independent experiments. ***P< 0.001 compared with control group, by two-way ANOVA.
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Albumin-induced increase in matrix metalloproteinase-9
is suppressed by inhibition of p38 mitogen-activated
protein kinase and extracellular signal regulated protein
kinase, but not c-Jun N-terminal kinase
We have previously shown that activation of astrocytes
induced by albumin involves activation of the MAPK
pathways [28]. We confirmed this finding here by show-
ing that treatment of the astrocytes with albumin for 90
minutes induced an increase in the level of phosphory-
lated p38 MAPK, ERK and JNK (Figure 2a).
To determine whether the activation of MMP-9 pro-
duced by albumin was mediated by MAPKs, we pre-
treated astrocytes with either the p38 MAPK inhibitor
SB203580, the ERK pathway inhibitor PD98059, or the
JNK inhibitor SP600125. We then exposed the cells to
albumin and measured MMP-9 activation after 24 hours
of recovery (Figure 2b-d). Inhibition of the p38 MAPK
pathway significantly attenuated the increase in MMP-9
induced by albumin (Figure 2b). Inhibition of the ERK
pathway significantly attenuated the increase in MMP-9
induced by albumin, but only at the highest concentra-
tion of inhibitor used (Figure 2c). In contrast, the release
of MMP-9 in response to albumin was not affected by
inhibition of JNK (Figure 2d). The level of MMP-2 mea-
sured in the conditioned media of astrocytes was not
affected by the presence of the MAPK inhibitors (data
not shown).
Albumin-induced increase in matrix metalloproteinase-9
is mediated via NADPH oxidase and reactive oxygen
species
Treatment of astrocytes with albumin induced an in-
crease in the production of ROS as measured by in-
crease in carboxy-H2DCF-DA fluorescence (Figure 3a)
compared with the control cells (inset, Figure 3a). Pre-
treatment of cells with a combination of the antioxidant
Figure 2 Albumin-induced increase in matrix metalloproteinase (MMP)-9 is dependent on the activation of mitogen-activated protein
kinase (MAPK) pathways. (a) Representative western blot shows that treatment with BSA for 90 minutes induced an increase in the level of
phosphorylated p38 MAPK, extracellular signal regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK). Representative zymogram and
corresponding quantification of the level of MMP-9 release by astrocytes treated with albumin in the presence (+) or absence (−) of (b) the p38
MAPK inhibitor SB203580, (c) the ERK pathway inhibitor PD98059, and (d) the JNK inhibitor SP600125. Inhibition of the p38 MAPK and ERK
pathways significantly suppressed the release of MMP-9 induced by albumin. whereas inhibition of JNK pathway did not modify the response to
albumin. Data are representative of mean± SEM of three independent experiments. **P< 0.01, ***P< 0.001 compared with the BSA-treated
group.
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enzymes PEG-SOD and PEG-CAT suppressed the DCF-
DA fluorescence caused by albumin, indicating that the
fluorescent signal was due to an increase in ROS. Expos-
ure to the positive control, TBHP, confirmed that
increased DCF-DA fluorescence can be detected in
astrocytes in the presence of oxidative stress.
Treatment with PEG-CAT alone, or in combination
with PEG-SOD, significantly suppressed the MMP-9
production induced by albumin (Figure 3b). However,
pre-treatment with PEG-SOD alone did not induce a
significant change in the level of MMP-9 produced by
astrocytes.
Next, we determined the role of NADPH oxidase in
albumin–induced production of MMP-9 by treating the
cells with the NADPH oxidase inhibitor, DPI (Figure 3c).
The increase in MMP-9 level induced by albumin treat-
ment was significantly suppressed by DPI. Taken to-
gether, these data suggest that ROS produced by
NADPH oxidase in astrocytes probably mediate the pro-
duction of MMP-9 by albumin in astrocytes. Neither of
Figure 3 Albumin-induced increase in matrix metalloproteinase (MMP)-9 involves reactive oxygen species. (a) Representative images of
5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCF-DA) fluorescence alone (green) or merged with DAPI nuclear stain
(blue) in astrocytes treated with BSA, PBS (inset) or BSA with polyethylene glycol–superoxide dismutase (PEG-SOD, 200U) or polyethylene
glycol–catalase (PEG-CAT) or the positive control tert-butyl hydroperoxide (TBHP). Treatment with albumin induced an increase in the DCF-DA
fluorescence in astrocytes that was suppressed by the presence of PEG-SOD and PEG-CAT. Bars represent 50 μm. The data represent two
independent experiments, each performed in duplicate. Representative zymogram and corresponding quantification of the level of MMP-9
release by astrocytes treated with albumin in the presence (+) or absence (−) of (b) PEG-SOD and PEG-CAT, and (c) the NADPH oxidase inhibitor,
diphenyleneiodonium chloride (DPI). Inhibition of albumin-induced increase in MMP-9 by antioxidant enzymes SOD and CAT and the NADPH
oxidase inhibitor, DPI suggest that the increase in MMP-9 involves reactive oxygen species. Data are representative of mean± SEM of three
independent experiments. ***P< 0.001 compared with the BSA-treated group.
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these inhibitors induced a change in the level of MMP-2
produced by astrocytes (data not shown).
Albumin-induced increase in p38 mitogen-activated
protein kinase and Jun kinase is downstream from
activation of NADPH oxidase
Next, we investigated whether the activation of MAPKs
by albumin was dependent on the production of ROS
(Figure 4). Inhibition of NADPH oxidase with DPI sup-
pressed the increase in the levels of phospho-p38 MAPK
induced by albumin treatment (Figure 4a). Treatment of
the astrocytes with DPI induced an increase in the level
of phospho-ERK measured in the astrocytes at the high-
est concentration (Figure 4b). DPI suppressed the in-
crease in the levels of phospho-JNK induced by albumin
treatment (Figure 4c).
Albumin-induced increase in matrix metalloproteinase-9
does not involve the transforming growth factor-β
receptor pathway
The TGF-β receptor has been previously shown to act as
a receptor for albumin on astrocytes [22,24]. We previ-
ously showed that the effect of albumin on astrocyte ac-
tivation partially involves the TGF-β receptor pathway,
including activation of the canonical Smad signaling
pathway [27]. Accordingly, we next investigated whether
the effects of albumin on MMP-9 production also
involved the TGF-β receptor pathway (Figure 5). Inhib-
ition of the TGF-β receptor I with SB431542 did not
affect the increase in MMP-9 induced by albumin (Fig-
ure 5a). Similarly, inhibition of the Smad pathway with
SIS3 did not suppress the increase in MMP-9 produced
by the albumin-treated astrocytes (Figure 5b). Consistent
with these data, treatment of astrocytes with TGF-β1
(10 ng/mL) did not alter the level of MMP-9 in astro-
cytes (Figure 5c). These data suggest that the increase in
MMP-9 induced by albumin in astrocytes occurs inde-
pendently of the TGF-β receptor and the Smad pathway.
Albumin induces an increase in tissue inhibitor of
metalloproteinase-1 production independent of mitogen-
activated protein kinase pathways
Treatment of astrocytes with albumin also induced the
production of endogenous inhibitor of MMP-9, TIMP-1
(Figure 6). The time course of expression of TIMP-1
after exposure to albumin was similar to activation of
MMP-9, with the maximum level reached at 24 hours
(Figure 6a). The level of TIMP-1 also increased over
time in the control group but was significantly lower
than the albumin-exposed group. The increase in TIMP-
1 was not suppressed by inhibition of the p38 MAPK,
ERK or JNK pathways (Figure 6b). Furthermore, inhib-
ition of TGF-β receptor I (Figure 6c) or the Smad path-
way (Figure 6d) did not suppress the increase in TIMP-1
induced by exposure to albumin. Finally, inhibition of
ROS generation by treatment with SOD and CAT (Fig-
ure 6e) did not suppress the increase in TIMP-1, and in-
hibition of NADPH oxidase by DPI (Figure 6f ) only
partially suppressed TIMP-1 increase at the highest con-
centration used.
Discussion
In this study, we found that albumin induces an increase
in the production of MMP-9 in astrocytes, and that this
increase requires generation of ROS and activation of
the MAPK pathway. These findings identify albumin as
Figure 4 Albumin-induced increase in p38 mitogen-activated protein kinase (MAPK) and Jun kinase (JNK) is mediated by reactive
oxygen species. Representative pictures and corresponding quantification of western blot of the level of phosphorylated (a) p38 MAPK, (b)
extracellular signal regulated protein kinase (ERK), and (c) JNK in cells treated with vehicle or BSA in the presence (+) or absence (−) of the
NADPH oxidase inhibitor, diphenyleneiodonium chloride (DPI). Treatment with DPI suppresses the increase in phospho-p38 MAPK and JNK but
induces a further increase in the level of phospho-ERK induced by albumin treatment. The data are representative of mean± SEM of two
independent experiments. * P< 0.05, ***P< 0.001 compared with the BSA-treated group.
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another signaling molecule in addition to thrombin
[19,36], which can activate MMP-9 in astrocytes. These
results link albumin to the diverse cellular responses
mediated by MMP-9, including neuronal injury, intracer-
ebral hemorrhage, epileptogenesis, and dendritic remod-
eling [2,3,10,37].
The implications of these data for the use of albumin in
cerebral injury in clinical practice are complex. The Saline
vs. Albumin Fluid Evaluation (SAFE) study identified a sig-
nificantly higher mortality rate in patients with severe TBI
assigned to albumin compared with the saline group [33].
In stroke subjects, the Albumin in Acute Stroke (ALIAS)
Trial showed a potential beneficial therapeutic effect for
albumin [34], and the second part of the ALIAS trial has
been started with more stringent exclusion criteria [38].
By contrast, pre-clinical [30,39,40] and clinical [41] data
indicate improved neurologic outcomes in patients with
stroke who were treated with albumin [42].
The contrasting effects of albumin in stroke and TBI re-
flect the complexity of the cellular responses to MMP-9.
Activation of MMPs results in the degradation of the com-
ponents of the vascular basement membrane, leading to
breakdown of the BBB. MMP-9 levels increase after acute
brain injuries including status epilepticus [11], and are
linked to increases in permeability of the BBB [10,12,43-
45]. In a mouse global cerebral ischemia model, neurologic
injury was reduced in MMP-9 knockout mice, in part due
to attenuated proteolysis of the BBB [46]. Deletion of
MMP-9 [47,48], or inhibition of MMP-9 activity [44,47,49],
improved neurologic function after TBI or stroke. Further-
more, suppression of the increase in MMPs produced by
closed head injury [50,51] or by stroke [52] results in a re-
duction of the brain edema and improved neurological re-
covery. However, other lines of evidence implicate MMP-9
in the mechanisms of epileptogenesis and synaptic remod-
eling [53]. MMP-9 KO mice show increased resistance to
pentylenetetrazole kindling–induced epilepsy [14]. Acting
through an integrin β1-dependent pathway, MMP-9 pro-
duces changes in dendritic spine morphology [2,3]. Our
finding that albumin increases MMP-9 activation in astro-
cytes suggests another pathway linking albumin to the
mechanisms of epileptogenesis mediated by the TGF-β re-
ceptor [22,24].
The link between activation of p38 MAPK, ERK and
MMP-9 found in the present study is consistent with the
well-established role for MAPK pathways in the produc-
tion of MMP-9 in astrocytes in response to different
stimuli [20,35,54,55]. Our data indicate a predominant
requirement for activation of p38 MAPK. By contrast,
the activation of MMP-9 produced by exposure to
thrombin acting via protease-activated receptor 1, or
stimulation of protein kinase C, is regulated by ERK1/2
[19,20]. This suggests that the specific MAPK involved
in signal transduction to MMP-9 will depend on the in-
citing stimulus. We speculate that the delay in produc-
tion of MMP-9 in astrocytes in response to albumin
Figure 5 Albumin-induced increase in matrix metalloproteinase (MMP)-9 occurs independently of the transforming growth factor
(TGF)-β receptor. Representative zymogram and corresponding quantification of the level of MMP-9 release by astrocytes treated with BSA in
the presence (+) or absence (−) of (a) the TGF-β receptor I inhibitor SB431542, or (b) the Smad pathway inhibitor SIS3; neither inhibition of the
TGF-β receptor I inhibitor nor the Smad pathway inhibited albumin-induced increase in MMP-9. (c) Representative zymogram of the level of
MMP-9 release by astrocytes treated with BSA and TGF-β1 (10 ng/mL). Data are representative of mean± SEM of three independent experiments.
***P< 0.001 compared with the BSA-treated group.
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reflects de novo protein synthesis through transcription
and translation, as shown previously in response to IL-
1β [54], which takes several hours. However, we cannot
exclude the possibility that MMP-9 increases earlier than
24 hours after injury.
The proteolytic activity of MMPs including MMP-9 is
regulated by TIMP-1 [15], and we found an increase in
TIMP-1 levels over time both in control and albumin-
exposed astrocytes. The concomitant changes in expres-
sion of metalloproteinases and their endogenous inhibitors
have been described in TBI [56] and in ischemia [57],
consistent with the increase in TIMP-1 we observed in re-
sponse to albumin. Evidence from other disease states in-
cluding experimental autoimmune encephalomyelitis and
spinal cord injury suggests that expression of TIMP-1
increases along with MMPs [58,59]. The in vivo effects of
the increase in MMP-9 may therefore be determined by
its activity relative to TIMP-1, as has been suggested for
the use of MMP-9 as a clinical biomarker in stroke [10].
The effects of albumin on astrocytes have been reported
to involve its binding to surface proteins that act as recep-
tors [22,60]. Our data suggest that the increase in MMP-9
Figure 6 Albumin stimulates an increase in the release of tissue inhibitor of metalloproteinase (TIMP)-1 in the conditioned media by
astrocytes. (a) Astrocytes exposed to BSA had a time-dependent increase in TIMP-1. (b) Levels of TIMP-1 in astrocytes treated with albumin in
the presence (+) or absence (−) of the TGF-β receptor I inhibitor SB431542. (c) Levels in astrocytes treated with albumin in the presence of the
p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 (SB), the extracellular signal regulated protein kinase (ERK) pathway inhibitor
PD98059 (PD), and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 (SP). (d) Levels in astrocytes treated with albumin in the presence (+) or
absence (−) of SIS3, the Smad pathway inhibitor. (e) Levels of TIMP-1 in astrocytes treated with albumin in the presence (+) or absence (−) of the
antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) or (f) the NADPH oxidase inhibitor diphenyleneiodonium chloride (DPI).
Data are representative of mean± SEM of 3–4 independent experiments, and are expressed (B-F) as a percentage of the value of the BSA-treated
group. **P< 0.01 compared with control-treated group. *P< 0.05 compared with BSA-treated group.
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induced by albumin occurs independently of the TGF-β
receptor–Smad pathway. We also found that treatment of
the cells with TGF-β1 did not increase the level of MMP-
9. Consistent with this result, we have previously shown
that exposure of astrocytes to TGF-β1 did not alter levels
of other inflammatory markers in astrocytes [27]. By con-
trast, treatment of an astrocyte cell line and primary astro-
cyte cultures with TGF-β1 has been reported to produce
an increase in MMP-9 [61]. The dose of TGF-β1 used in
the present study is lower (10 ng/ml) than that used
(15 ng/ml) by Hsieh and colleagues, which may account
for the difference in the responses.
We found that an increase ROS was required for activa-
tion of MMP-9 induced by albumin. This is consistent
with previous reports showing that ROS are involved in
the production of MMP-9 by astrocytes in response to
other stimuli, including IL-1β [62], TGF-β [61], and
hemoglobin [18].
The effects of albumin on other components of the neu-
rovascular unit, including endothelial cells, are not well
understood. In endothelial cells, oxidative stress can in-
duce degradation of basal membranes proteins by MMPs,
which leads to BBB injury [37]. Albumin has been shown
to bind to endothelial cells resulting in the activation of
the TGF-β pathway [63]. However, the effects of albumin
on the production of MMP-9 from other components of
the neurovascular bundle remain to be determined.
Compromise of the BBB after TBI, stroke, or status
epilepticus may expose the brain parenchyma to high
molecular weight proteins from which it is normally
protected. Of these proteins, both albumin and throm-
bin have been implicated in pathophysiologic processes
including epileptogenesis [11,24] and intracerebral
hemorrhage [16]. Acting through protease-activated re-
ceptor-1, thrombin activates MMP-9 in astrocytes [19], a
mechanism linked to the pathogenesis of intracerebral
hemorrhage after administration of tissue plasminogen
for treatment of stroke [7]. In vivo, it is likely that the
brain parenchyma is exposed to thrombin and albumin
simultaneously with MMP-9, and studies are needed to
investigate these responses, as has been previously car-
ried out for the combined effects of thrombin and
MMP-9 [36,64].
Conclusions
In summary, these results link albumin acting through
ROS and the p38 MAPK, to the activation of MMP-9 in
astrocytes. Numerous studies identify a role for MMP-9
in the mechanisms of compromise of the BBB, epilepto-
genesis or synaptic remodeling after ischemia or TBI
[9,10,12,14]. The increase in MMP-9 produced by albu-
min further implicates both astrocytes and albumin in
the acute and long-term complications of acute CNS
insults, including cerebral edema and epilepsy.
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